Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) shares saw an uptick in trading volume on Monday . 26,203 shares were traded during mid-day trading, an increase of 90% from the previous session’s volume of 13,775 shares.The stock last traded at $18.13 and had previously closed at $18.60.
Wall Street Analysts Forecast Growth
TLX has been the subject of a number of research reports. William Blair raised Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a research report on Tuesday, November 19th. UBS Group raised their price target on shares of Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, January 27th.
Check Out Our Latest Research Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Stock Performance
About Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.
Read More
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Apple Comes Out From Behind to Emerge as An AI-Services Leader
- 3 Stocks to Consider Buying in October
- Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Big Dividend Hikes: 4 Large-Cap Stocks Increasing Payouts
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
